Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Council of Science and Technology, Mexico | OTHER |
Not provided
Not provided
Not provided
The purpose of this study is to investigate the short and long term clinical and cognitive effects of repetitive Transcranial Magnetic Stimulation (rTMS) at 5 Hz and/or 10 Hz frequencies on the left dorsolateral prefrontal cortex in cocaine dependent patients and to examine possible changes in brain structure and functional connectivity associated with this intervention.
Repetitive transcranial magnetic stimulation (rTMS) has been shown to reduce craving in cocaine addicts in the short term. However, there are no studies on the long term clinical and cognitive effects of sustained rTMS therapy. Moreover, clinical improvement or decline could be related to long term changes in brain structure and function. The purpose of this study is to investigate the short and long term clinical and cognitive effects of repetitive Transcranial Magnetic Stimulation (rTMS) at 5 Hz and/or 10 Hz frequencies on the left dorsolateral prefrontal cortex in cocaine dependent patients and to examine possible changes in brain structure and functional connectivity associated with this intervention. For this purpose the investigators will recruit cocaine dependent patients and stimulate them using rTMS with a acute intervention (twice a day for 2 weeks) and a maintenance intervention (twice a week for 3 months). The investigators will follow the patients to determine clinical outcome. The investigators will also measure clinical, cognitive and brain structural and functional connectivity to asses changes related to the intervention in the short and long term (measurements at: baseline, 2 weeks and 3 months).
Procedure:
The projects consists of: Screening Visit, Part 1 and Part 2.
First, there will be a screening visit, where a clinical interview will be conducted and tests will be applied to select study participants who meet the inclusion and exclusion criteria.
Baseline clinical, cognitive and neuroimaging data will be acquired. The cognitive and neuroimaging data will be exploratory, to be associated with the outcome measures. Part 1 of the study entails the determination of the rTMS target frequency (5 or 10 Hz) for Part 2 (long term stimulation). In Part 1, all participants will be randomly assigned to one of the four treatment legs with rTMS (10Hz, 10Hz-Sham, 5Hz, 5Hz-Sham). Participants will receive 20 sessions of rTMS (intervention or sham), twice per day for 10 consecutive days. Each session lasts approximately 35 minutes.
At 2 weeks, the investigators will evaluate the short term effect of treatment by measuring clinical, cognitive and neuroimaging changes and select which frequency of stimulation is the most effective in terms of clinical improvement, but also in terms of the rate of secondary effects. Our hypothesis is that 5 Hz is as effective as 10 Hz without the high rate of secondary effects (i.e. seizures).
In Part 2 of the study, the sham groups will end and they will be invited to the treatment condition although they data not will be considered for later phases. Here the maintenance phase starts (long term), where rTMS will be performed twice a week for 12 months using the target frequency (5 or 10 Hz). Clinical, cognitive and neuroimaging data will be acquired at 2 weeks and 3 months.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active rTMS frequency at 5 Hz | Active Comparator | The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive treatment stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 5 Hz, that includes 2 sessions per day for 10 consecutive business days for 2 weeks. Then a target frequency will be determined for the remaining of the study. If this arm's target frequency is chosen, then the participants will receive the maintenance intervention of 2 sessions per week for 12 months. Each session will consist of the application of rTMS at a frequency of 5Hz, to 100% of the motor threshold. |
|
| Sham rTMS frequency at 5 Hz | Sham Comparator | The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with a coil that allows simulated stimulation (Coil AP) at a frequency of 5 Hz, with the software necessary for the operator to remain blind to the stimulation condition. This arm will only last for 2 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Repetitive Transcranial Magnetic Stimulation | Device | The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral. Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Cocaine Craving (CCQ) | The craving will be measured using a craving questionnaire for cocaine validated in Mexican population (Cocaine Craving Questionnaire or CCQ). | Baseline, 2 weeks, 3 months |
| Change in Cocaine Craving (VAS) | The craving will be measured using a 100 mm visual analogue scales (VAS). | Baseline, 2 weeks, 3 months |
| Change in Cocaine Urine Test | Frequency of cocaine use will be measured using reagent strips from Instant View drug screening (> 300 ng/mL). Results are Positive or Negative. | Baseline, 2 weeks, 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Psychopathological Symptoms | Measured by the 90 Symptoms Questionnaire (SCL-90). | Baseline, 2 weeks, 3 months |
| Changes in Depression | Measured by Hamilton Depression Rating Scale (HDRS) (21 items). |
Not provided
Inclusion Criteria:
Contraceptive measures will be reviewed with the female subjects at each visit prior to the rTMS treatment.
Exclusion Criteria:
These data will be corroborated by a screening visit where the following instruments will be used:
Clinical Interview. Self-applicable demographic questionnaire. Mini International Neuropsychiatric Interview (MINI-Plus). Structured clinical interview for DSM Axis II, self report (SCID-II).
Elimination criteria:
The participation of all participants during the study will be suspended if:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ruth Alcala-Lozano, MD, MSc | Contact | +52(55)41605065 | ruthalcala_@hotmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Eduardo A Garza-Villarreal, MD, PHD | Universidad Nacional Autonoma de Mexico | Principal Investigator |
| Ruth Alcala-Lozano, MD, MSc | Instituto Nacional de Psiquiatria "Ramon de la Fuente Muñiz" | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Instituto Nacional de PsiquiatrÃa "Ramón de la Fuente Muñiz" | Recruiting | Mexico City | 14370 | Mexico |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42106690 | Derived | Han Z, Liu T, Wang K, Yang G, Yan T. Structural connectome architecture and biological vulnerability shape cortical atrophy in cocaine use disorder. BMC Med. 2026 May 9;24(1):374. doi: 10.1186/s12916-026-04903-y. | |
| 33508499 | Derived | Garza-Villarreal EA, Alcala-Lozano R, Fernandez-Lozano S, Morelos-Santana E, Davalos A, Villicana V, Alcauter S, Castellanos FX, Gonzalez-Olvera JJ. Clinical and Functional Connectivity Outcomes of 5-Hz Repetitive Transcranial Magnetic Stimulation as an Add-on Treatment in Cocaine Use Disorder: A Double-Blind Randomized Controlled Trial. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jul;6(7):745-757. doi: 10.1016/j.bpsc.2021.01.003. Epub 2021 Jan 26. |
Not provided
Not provided
After the main publications by the group are released, all data (clinical, cognitive and neuroimaging) will be uploaded to an online open server such as LONI or OpenfMRI, for example.
Not provided
Not provided
Not provided
Not provided
Not provided
Double-blind randomized control trial
Not provided
Not provided
Not provided
|
| Repetitive Transcranial Magnetic Stimulation (Sham) | Device | The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP). This condition will only last two weeks. |
|
| Baseline, 2 weeks, 3 months |
| Changes in Anxiety | Measured by Hamilton Anxiety Rating Scale (HARS). | Baseline, 2 weeks, 3 months |
| Changes in Drug Consumption and Related Problems | Measured by the Addiction Severity Index (ASI-lite). | Baseline, 2 weeks, 3 months |
| Changes in Sleep Quality: PSQI | Measured by the Pittsburgh Sleep Quality Index (PSQI). | Baseline, 2 weeks, 3 months |
| Changes in Impulsivity | Measured by the Barrat Impulsivity Scale-11 (BIS-11). | Baseline, 2 weeks, 3 months |
| Lapse rate | Lapse is defined as at least one consumption event not in the same pattern as the baseline consumption. The report of self-consumption of cocaine and urine drug tests, with special attention to the presence of traces of cocaine. | Baseline, 2 weeks, 3 months |
| Relapse rate | Relapse is defined as consumption events in the same pattern as the baseline consumption. The report of self-consumption of cocaine and urine drug tests, with special attention to the presence of traces of cocaine. | Baseline, 2 weeks, 3 months |
| ID | Term |
|---|---|
| D019970 | Cocaine-Related Disorders |
| D016739 | Behavior, Addictive |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D003192 | Compulsive Behavior |
| D007175 | Impulsive Behavior |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D050781 | Transcranial Magnetic Stimulation |
| ID | Term |
|---|---|
| D055909 | Magnetic Field Therapy |
| D013812 | Therapeutics |
Not provided
Not provided